Pembrolizumab
可瑞达 (Keytruda)
The world's best-selling immunotherapy: a PD-1 checkpoint inhibitor that releases the brakes on your immune system so it attacks the tumor.
At a glance
China price
¥17,918 per 100mg vial
What this meansChecked against a primary or official source.
Source(s)
- health.baidu.com/m/detail/ar_6101301212440287301
Secondary source (media / community / commercial) - aihope.cn/article/detail/7077
Secondary source (media / community / commercial)
Last checked2026-09-08
Notesnational reference retail price
NRDL (national insurance)
Not in NRDL — self-pay in China; patient-assistance programs common.
Regulatory status
NMPA approved; NOT in NRDL (self-pay; patient assistance programs exist)
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
International comparison
US list ~USD 5,800 per 100mg equivalent → China ≈ 40-45% of US at list
What this meansReported information that has not yet been independently confirmed.
SourceNo independent source on file.
NotesReported comparison, not independently verified.
What it treats
Broad: melanoma, NSCLC, and multiple other tumor types per Chinese label.
How it is accessed in China
- Hospitals nationwide
- DTP pharmacies
Charity assistance programs materially lower effective annual cost in China.
Sources & verification
- health.baidu.com/m/detail/ar_6101301212440287301 — Secondary source (media / community / commercial)
- aihope.cn/article/detail/7077 — Secondary source (media / community / commercial)
Reader discussion
Public comments about Pembrolizumab. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.